Circulation最新文献

筛选
英文 中文
Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial. 达格列净用于心脏移植受者肾脏保护:一项随机临床试验。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.083760
Stine Holmen, Olivier Manintveld, Kevin Damman, Ida Haugen Löfman, Mariusz Szymanski, Oscar Braun, Martin Lando, Elisabeth Bjørkelund, Jasper J Brugts, Yannick J H J Taverne, Jozine M Ter Maaten, Tonje Thorvaldsen, Michael Melin, Manon G van der Meer, Morten W Fagerland, Håvard Ravnestad, Einar Gude, Arne K Andreassen, Lars Gullestad, Kaspar Broch
{"title":"Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.","authors":"Stine Holmen, Olivier Manintveld, Kevin Damman, Ida Haugen Löfman, Mariusz Szymanski, Oscar Braun, Martin Lando, Elisabeth Bjørkelund, Jasper J Brugts, Yannick J H J Taverne, Jozine M Ter Maaten, Tonje Thorvaldsen, Michael Melin, Manon G van der Meer, Morten W Fagerland, Håvard Ravnestad, Einar Gude, Arne K Andreassen, Lars Gullestad, Kaspar Broch","doi":"10.1161/CIRCULATIONAHA.126.083760","DOIUrl":"10.1161/CIRCULATIONAHA.126.083760","url":null,"abstract":"<p><strong>Background: </strong>Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may attenuate the decline in kidney function, but evidence in heart transplant recipients is limited.</p><p><strong>Methods: </strong>The DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT) trial is a multicenter, double-blind, randomized, placebo-controlled trial conducted at six heart transplant centers in Northern Europe. We randomized adult heart transplant recipients with an estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m<sup>²</sup> at least one year after transplantation 1:1 to receive dapagliflozin 10 mg or matching placebo once daily. The primary endpoint was the slope of the eGFR from 2 weeks after treatment initiation to the end of the 12-month blinded treatment period.</p><p><strong>Results: </strong>Between June 2022 and September 2025, we randomized 430 participants, of whom 217 were allocated to dapagliflozin and 213 were allocated to placebo. We included the 424 patients with at least one eGFR measurement after baseline in the full analysis set. Their mean age was 53 ± 14 years and 29& were women. The eGFR at baseline was 67 ± 22 mL/min/1.73 m<sup>2</sup>. The median time from transplantation was 7 (3 - 13) years. Dapagliflozin improved the chronic slope of the eGFR compared with placebo. The change in the eGFR from 2 weeks to 12 months after treatment initiation was 2.0 (95% confidence interval [CI] 1.0 - 3.1) mL/min/1.73 m<sup>2</sup> in the dapagliflozin group and 0.3 (95% CI -0.8 - 1.4) mL/min/1.73 m<sup>2</sup> in the placebo group for a between-group difference of 1.7 (95% confidence interval 0.1 - 3.3) mL/min/1.73 m<sup>²</sup>; p = 0.03. There were no unexpected safety signals and similar rates of adverse events, including infections, between groups.</p><p><strong>Conclusions: </strong>In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial. 保留射血分数的心力衰竭患者的铁补充:IRONMET-HFpEF随机试验。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.084009
Gregory D Lewis, Nora K Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, Paridhi Gupta, Carly Camphausen, Laura Caccamo, Charounipha Soydara, Shaina McGinnis, Chloe Newlands, Skyler Williams, Alexandra Minasian, Nicholas Iskenderian, Isabela Landsteiner, Bhavani Iyer, Justin Joseph, Alvaro Delgado, Helena Tattersfield, Elizabeth Moore, Veronica Platt, Sujin Lee, Rajeev Malhotra
{"title":"Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial.","authors":"Gregory D Lewis, Nora K Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, Paridhi Gupta, Carly Camphausen, Laura Caccamo, Charounipha Soydara, Shaina McGinnis, Chloe Newlands, Skyler Williams, Alexandra Minasian, Nicholas Iskenderian, Isabela Landsteiner, Bhavani Iyer, Justin Joseph, Alvaro Delgado, Helena Tattersfield, Elizabeth Moore, Veronica Platt, Sujin Lee, Rajeev Malhotra","doi":"10.1161/CIRCULATIONAHA.126.084009","DOIUrl":"10.1161/CIRCULATIONAHA.126.084009","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Iron deficiency is present in &gt;50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ([Formula: see text]) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak [Formula: see text] in heart failure with preserved ejection fraction with iron deficiency.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin &lt;100 ng/mL or &lt;300 ng/mL with transferrin saturation &lt;20%. Participants were enrolled between December 2021 and April 2026. Single-dose ferric derisomaltose (1000 mg; n=44) or placebo (n=21) was administered once intravenously. The primary end point was the change in peak [Formula: see text] from baseline to 12 weeks with an analysis of covariance model including terms for treatment group, baseline peak [Formula: see text], and sex. Secondary end points included changes in [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class, health status assessed by the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score, and iron biomarkers at 12 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 65 randomized participants (median age, 68 years [interquartile range, 58-76 years], 72% women, transferrin saturation 16.0±7.4%, ferritin 57.8±48.9 ng/mL), 64 (98.5%) completed the study. The median baseline peak [Formula: see text] was 12.7 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt; (interquartile range, 10.6-15.8 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt;) in the FDI group and 12.2 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt; (11.6-14.6 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt;) in the placebo group. At 12 weeks, peak [Formula: see text] improved by 1.2 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt; (95% CI, 0.6-1.7) in the FDI group and was unchanged (0.1 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt; [95% CI, -0.7 to 0.9]) in the placebo group (least-squares mean difference, 1.1 mL·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt; [95% CI, 0.2-1.9]; &lt;i&gt;P&lt;/i&gt;=0.02). [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, and New York Heart Association class also improved in the FDI compared with the placebo group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05), whereas the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score did not differ significantly between groups (FDI group, +4.4 [95% CI, -2.4 to 11.2]; &lt;i&gt;P&lt;/i&gt;=0.20). FDI increased transferrin saturation (9.4% [95% CI, 4.9%-13.9%]) and ferritin (183 ng/mL [95% CI, 128-238]) compared with the placebo group (&lt;i&gt;P&lt;/i&gt;&lt;sub&gt;LSMD&lt;/sub&gt;&lt;0.001 for both). There were no serious adverse events related to FDI admin","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Against All Odds: A New CADENCE in Cardiopulmonary Remodeling. 排除万难:心肺重塑的新节奏。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.084161
Monica Mukherjee, Harm-Jan Bogaard
{"title":"Against All Odds: A New CADENCE in Cardiopulmonary Remodeling.","authors":"Monica Mukherjee, Harm-Jan Bogaard","doi":"10.1161/CIRCULATIONAHA.126.084161","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084161","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Potential New Therapeutic Option for Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction. 心力衰竭患者运动不耐受和保留射血分数的潜在新治疗选择。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.084111
Dalane W Kitzman, Robert J Mentz
{"title":"A Potential New Therapeutic Option for Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction.","authors":"Dalane W Kitzman, Robert J Mentz","doi":"10.1161/CIRCULATIONAHA.126.084111","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084111","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron Repletion in HFpEF: An Endpoint Is Not Yet an Indication. 铁补充在HFpEF:终点还不是一个适应症。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.084114
Marat Fudim, Andrew P Ambrosy
{"title":"Iron Repletion in HFpEF: An Endpoint Is Not Yet an Indication.","authors":"Marat Fudim, Andrew P Ambrosy","doi":"10.1161/CIRCULATIONAHA.126.084114","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084114","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protecting the Kidneys After Replacing the Heart: Another Role for SGLT2 Inhibitors. 替代心脏后保护肾脏:SGLT2抑制剂的另一个作用
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.084065
Dilushi Wijayaratne, Richard Haynes
{"title":"Protecting the Kidneys After Replacing the Heart: Another Role for SGLT2 Inhibitors.","authors":"Dilushi Wijayaratne, Richard Haynes","doi":"10.1161/CIRCULATIONAHA.126.084065","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084065","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Patients With Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND. 晚期慢性肾病患者稳定冠状动脉疾病初始侵袭性或保守性治疗后的长期生存:缺血- ckd EXTEND
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-07 DOI: 10.1161/CIRCULATIONAHA.126.083858
Sripal Bangalore, David J Maron, Rebecca Anthopolos, Harmony R Reynolds, Yifan Xu, Michelle Chang, Stephanie Boumakis, Jose Lopez-Sendon, Roxy Senior, Shaun G Goodman, Sean M O'Brien, Jerome L Fleg, Judith S Hochman
{"title":"Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Patients With Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND.","authors":"Sripal Bangalore, David J Maron, Rebecca Anthopolos, Harmony R Reynolds, Yifan Xu, Michelle Chang, Stephanie Boumakis, Jose Lopez-Sendon, Roxy Senior, Shaun G Goodman, Sean M O'Brien, Jerome L Fleg, Judith S Hochman","doi":"10.1161/CIRCULATIONAHA.126.083858","DOIUrl":"10.1161/CIRCULATIONAHA.126.083858","url":null,"abstract":"<p><strong>Background: </strong>In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown.</p><p><strong>Methods: </strong>Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality.</p><p><strong>Results: </strong>Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively.</p><p><strong>Conclusions: </strong>In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-ECG: Gatekeeper-in-Training for Population-level Atrial Fibrillation Screening. AI-ECG:人群水平心房颤动筛查的训练中的守门人。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-07 DOI: 10.1161/CIRCULATIONAHA.126.083888
Kelly Arps
{"title":"AI-ECG: Gatekeeper-in-Training for Population-level Atrial Fibrillation Screening.","authors":"Kelly Arps","doi":"10.1161/CIRCULATIONAHA.126.083888","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083888","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data, Information, and Action: The Promises and Limits of AI-Enabled Electrocardiography. 数据、信息和行动:人工智能心电图的前景和局限。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-07 DOI: 10.1161/CIRCULATIONAHA.126.083999
Kenneth M Stein
{"title":"Data, Information, and Action: The Promises and Limits of AI-Enabled Electrocardiography.","authors":"Kenneth M Stein","doi":"10.1161/CIRCULATIONAHA.126.083999","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083999","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor versus Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction. DAPT-SHOCK-AMI随机试验的多模态心脏成像亚研究:超声心动图和心脏磁共振评价坎格瑞洛与粉碎替格瑞洛在心源性休克合并急性心肌梗死中的作用。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-07 DOI: 10.1161/CIRCULATIONAHA.126.083929
Zuzana Motovska, Oana Ionita, Marco Guglielmo, Milan Hromadka, Jan Baxa, Roberto Tarantini, Martin Kotrc, Roman Panovsky, Tobias Geisler, Martin Novak, Jiri Weichet, Dana Kautznerova, Petr Kuchynka, Tomas Ondrus, Gilles Montalescot, Jiri Jarkovsky, Jan Lhotsky, Nina Ajmone Marsan, Teodora Vichova, Petr Klofac, Andrea Andrasova, Robin Nijveldt, Monika Cani, Jan Precek, Libor Gajdusek, Martin Masek, Martin Penicka, Stanislav Bartus, Zbynek Tudos, Jiri Kettner, Ota Hlinomaz, Jan Belohlavek, Petr Kala, Pavol Tomasov, Deepak L Bhatt
{"title":"Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor versus Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction.","authors":"Zuzana Motovska, Oana Ionita, Marco Guglielmo, Milan Hromadka, Jan Baxa, Roberto Tarantini, Martin Kotrc, Roman Panovsky, Tobias Geisler, Martin Novak, Jiri Weichet, Dana Kautznerova, Petr Kuchynka, Tomas Ondrus, Gilles Montalescot, Jiri Jarkovsky, Jan Lhotsky, Nina Ajmone Marsan, Teodora Vichova, Petr Klofac, Andrea Andrasova, Robin Nijveldt, Monika Cani, Jan Precek, Libor Gajdusek, Martin Masek, Martin Penicka, Stanislav Bartus, Zbynek Tudos, Jiri Kettner, Ota Hlinomaz, Jan Belohlavek, Petr Kala, Pavol Tomasov, Deepak L Bhatt","doi":"10.1161/CIRCULATIONAHA.126.083929","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083929","url":null,"abstract":"<p><strong>Background: </strong>In acute myocardial infarction complicated by cardiogenic shock (AMI-CS), the myocardium sustains a dual injury: ischemia of the culprit territory and global hypoperfusion from low cardiac output. Whether platelet inhibition at reperfusion affects the microcirculation, the infarct, the noninfarcted myocardium, and ventricular function, and over what time course, has not been examined with serial imaging. The prespecified multimodality imaging substudy of the randomized DAPT-SHOCK-AMI trial (intravenous cangrelor versus crushed oral ticagrelor) addressed this question.</p><p><strong>Methods: </strong>Patients at prespecified imaging sites underwent serial echocardiography (208 enrolled; evaluable examinations in 175, 120, and 99 patients in the acute phase, at 1 month, and at 1 year) and cardiac magnetic resonance (CMR; 93 enrolled; 73, 68, and 63); 81 patients (40 and 41) underwent both modalities. Blinded core laboratories analyzed all studies. The primary imaging endpoint was microvascular obstruction (MVO) on acute CMR, evaluable in 60 patients; secondary endpoints were infarct size, native T1 of the global, infarcted, and remote myocardium, left ventricular (LV) ejection fraction (LVEF), global longitudinal strain (GLS), E/e', and left atrial volume, and their changes. Comparisons between the cangrelor and crushed ticagrelor arms used covariate-adjusted logistic or linear regression; the substudy was not separately powered.</p><p><strong>Results: </strong>The odds of acute MVO were lower with cangrelor (adjusted odds ratio 0.27 [95% CI 0.08 to 0.98]; P=0.023). Infarct size did not differ between the arms. At 1 year, native T1 of the remote myocardium was lower with cangrelor (adjusted mean 1114 [95% CI 1057 to 1171] versus 1171 [1115 to 1228] ms; P=0.005). Over 1 year, LVEF increased more with cangrelor on echocardiography (37.9% versus 21.7% of the acute value; adjusted P=0.046) and CMR (15.8% versus 2.1%; P=0.027), with greater improvement in GLS, lower E/e', and less left atrial enlargement; no parameter differed between the arms at 1 month.</p><p><strong>Conclusions: </strong>In AMI-CS, serial multimodality imaging characterized microvascular, tissue-level, and functional injury over 1 year. Cangrelor was associated with less acute MVO, lower remote native T1, and more complete recovery of LV function than crushed ticagrelor, without a difference in infarct size; these hypothesis-generating findings suggest differences in the microcirculation and non-infarcted myocardial injury but do not establish a treatment mechanism.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书